Literature DB >> 34862698

Recurrent PTBP1::MAML2 fusions in composite hemangioendothelioma with neuroendocrine differentiation: A report of two cases involving neck lymph nodes.

Josephine K Dermawan1, William H Westra2, Cristina R Antonescu1.   

Abstract

Composite hemangioendothelioma (CHE) displaying neuroendocrine differentiation is a rare histologic variant that is often mistaken for angiosarcoma, having a predilection for visceral locations and being associated with an aggressive clinical course. Their pathogenesis is still evolving, with only two cases to date from separate studies reporting a recurrent PTBP1-MAML2 fusion. Herein, we report two new cases of neuroendocrine CHE harboring PTBP1-MAML2 fusions occurring in two elderly patients (70-year-old male and 71-year-old female), both involving neck lymph nodes. The first case presented with multifocal cervical lymphadenopathy, while the second case occurred unifocally in an enlarged neck lymph node. Histologically, the tumors displayed heterogenous architectural patterns with areas reminiscent of benign cavernous hemangioma, retiform hemangioendothelioma, epithelioid hemangioendothelioma, and angiosarcoma. Cytologically, the cells were monotonous with round to ovoid nuclei, open to fine chromatin, scant to moderate cytoplasm, and frequent vacuolization. In addition, the first case showed focal solid areas of large epithelioid cells with severe nuclear atypia, enlarged nuclei and prominent nucleoli, resembling epithelioid angiosarcoma. Tumor cells were diffusely positive for vascular markers and focally positive for synaptophysin. In both cases, a next-generation sequencing fusion panel confirmed an in-frame fusion between PTBP1 exon 10 and MAML2 exon 2. One case with clinical follow-up showed stable recurrent disease and metastatic lung deposits following treatment. Both patients were alive at 3 months and 1 year following initial diagnosis. Our findings lend further support to classifying CHE with PTBP1-MAML2 fusions as a distinct variant of CHE with unique clinicopathologic features, including neuroendocrine features.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  MAML2; PTBP1; composite hemangioendothelioma; fusion; neuroendocrine

Mesh:

Substances:

Year:  2021        PMID: 34862698      PMCID: PMC8895320          DOI: 10.1002/gcc.23017

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant.

Authors:  Kyle D Perry; Alyaa Al-Lbraheemi; Brian P Rubin; Jin Jen; Hongzheng Ren; Jin Sung Jang; Asha Nair; Jaime Davila; Stefan Pambuccian; Andrew Horvai; William Sukov; Henry D Tazelaar; Andrew L Folpe
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

2.  Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions.

Authors:  Marina Vivero; Phani Davineni; Valentina Nardi; John K C Chan; Lynette M Sholl
Journal:  Mod Pathol       Date:  2019-10-22       Impact factor: 7.842

3.  Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.

Authors:  Shigeki Sekine; Tohru Kiyono; Eijitsu Ryo; Reiko Ogawa; Susumu Wakai; Hitoshi Ichikawa; Koyu Suzuki; Satoru Arai; Koji Tsuta; Mitsuaki Ishida; Yuko Sasajima; Naoki Goshima; Naoya Yamazaki; Taisuke Mori
Journal:  J Clin Invest       Date:  2019-05-30       Impact factor: 14.808

4.  The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival.

Authors:  Baofeng Jin; Huangxuan Shen; Shuibin Lin; Jian-Liang Li; Zirong Chen; James D Griffin; Lizi Wu
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

5.  Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors.

Authors:  Lizi Wu; Tao Sun; Karla Kobayashi; Ping Gao; James D Griffin
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

6.  Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases.

Authors:  E Calonje; C D Fletcher; E Wilson-Jones; J Rosai
Journal:  Am J Surg Pathol       Date:  1994-02       Impact factor: 6.394

7.  Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival.

Authors:  Marie-Clotilde Alves-Guerra; Chiara Ronchini; Anthony J Capobianco
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Cutaneous composite hemangioendothelioma with satellitosis and lymph node metastases.

Authors:  Luis Requena; José Luis Díaz; Felix Manzarbeitia; Rosario Carrillo; Jesús Fernández-Herrera; Heinz Kutzner
Journal:  J Cutan Pathol       Date:  2008-02       Impact factor: 1.587

Review 9.  A Dynamic Role of Mastermind-Like 1: A Journey Through the Main (Path)ways Between Development and Cancer.

Authors:  Sabrina Zema; Maria Pelullo; Francesca Nardozza; Maria Pia Felli; Isabella Screpanti; Diana Bellavia
Journal:  Front Cell Dev Biol       Date:  2020-12-21

10.  Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.

Authors:  Guo Zhu; Ryma Benayed; Caleb Ho; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Ryan Berry; Brian P Rubin; Khedoudja Nafa; Lu Wang; David S Klimstra; Marc Ladanyi; Meera R Hameed
Journal:  Mod Pathol       Date:  2018-11-21       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.